Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Resistance mechanisms to SYK inhibition in acute myeloid leukemia.

Cremer A, Ellegast JM, Alexe G, Frank ES, Ross L, Chu SH, Pikman Y, Robichaud A, Goodale A, Haupl B, Mohr S, Rao AV, Walker A, Blachly JS, Piccioni F, Armstrong SA, Byrd JC, Oellerich T, Stegmaier K.

Cancer Discov. 2019 Nov 26. pii: CD-19-0209. doi: 10.1158/2159-8290.CD-19-0209. [Epub ahead of print]

PMID:
31771968
2.

RET-mediated autophagy suppression as targetable co-dependence in acute myeloid leukemia.

Rudat S, Pfaus A, Cheng YY, Holtmann J, Ellegast JM, Bühler C, Marcantonio DD, Martinez E, Göllner S, Wickenhauser C, Müller-Tidow C, Lutz C, Bullinger L, Milsom MD, Sykes SM, Fröhling S, Scholl C.

Leukemia. 2018 Oct;32(10):2189-2202. doi: 10.1038/s41375-018-0102-4. Epub 2018 Mar 22.

PMID:
29654265
3.

Identification of an allosteric benzothiazolopyrimidone inhibitor of the oncogenic protein tyrosine phosphatase SHP2.

LaRochelle JR, Fodor M, Ellegast JM, Liu X, Vemulapalli V, Mohseni M, Stams T, Buhrlage SJ, Stegmaier K, LaMarche MJ, Acker MG, Blacklow SC.

Bioorg Med Chem. 2017 Dec 15;25(24):6479-6485. doi: 10.1016/j.bmc.2017.10.025. Epub 2017 Oct 20.

PMID:
29089257
4.

MPL expression on AML blasts predicts peripheral blood neutropenia and thrombocytopenia.

Rauch PJ, Ellegast JM, Widmer CC, Fritsch K, Goede JS, Valk PJ, Löwenberg B, Takizawa H, Manz MG.

Blood. 2016 Nov 3;128(18):2253-2257. Epub 2016 Aug 29.

PMID:
27574191
5.

inv(16) and NPM1mut AMLs engraft human cytokine knock-in mice.

Ellegast JM, Rauch PJ, Kovtonyuk LV, Müller R, Wagner U, Saito Y, Wildner-Verhey van Wijk N, Fritz C, Rafiei A, Lysenko V, Dudkiewicz E, Theocharides AP, Soldini D, Goede JS, Flavell RA, Manz MG.

Blood. 2016 Oct 27;128(17):2130-2134. Epub 2016 Aug 31.

6.

Peripheral blood CD34+ cells efficiently engraft human cytokine knock-in mice.

Saito Y, Ellegast JM, Rafiei A, Song Y, Kull D, Heikenwalder M, Rongvaux A, Halene S, Flavell RA, Manz MG.

Blood. 2016 Oct 6;128(14):1829-1833. doi: 10.1182/blood-2015-10-676452. Epub 2016 Aug 19.

7.

Generation of Humanized Mice for Analysis of Human Dendritic Cells.

Saito Y, Ellegast JM, Manz MG.

Methods Mol Biol. 2016;1423:309-20. doi: 10.1007/978-1-4939-3606-9_22.

PMID:
27142026
8.

Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33.

Azoitei N, Hoffmann CM, Ellegast JM, Ball CR, Obermayer K, Gößele U, Koch B, Faber K, Genze F, Schrader M, Kestler HA, Döhner H, Chiosis G, Glimm H, Fröhling S, Scholl C.

J Exp Med. 2012 Apr 9;209(4):697-711. doi: 10.1084/jem.20111910. Epub 2012 Mar 26.

9.

Metastasis of osteosarcoma after 16 years.

Ellegast J, Barth TF, Schulte M, Bielack SS, Schmid M, Mayer-Steinacker R.

J Clin Oncol. 2011 Jan 20;29(3):e62-6. doi: 10.1200/JCO.2010.30.8312. Epub 2010 Nov 1. No abstract available.

PMID:
21041714
10.

5'-Triphosphate RNA is the ligand for RIG-I.

Hornung V, Ellegast J, Kim S, Brzózka K, Jung A, Kato H, Poeck H, Akira S, Conzelmann KK, Schlee M, Endres S, Hartmann G.

Science. 2006 Nov 10;314(5801):994-7. Epub 2006 Oct 12.

Supplemental Content

Loading ...
Support Center